Panitumumab

About

Therapy type: Targeted therapy

Therapy strategy: EGFR inhibition

Mappings

NCI Thesaurus: Panitumumab (ncit:C1857)

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
Sensitivity (+) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab